HMG-CoA reductase inhibitors and P-glycoprotein modulation

British Journal of Pharmacology

Volumn 132, Issue 6, 2001, Pages 1183-1192

  Bogman, Katrijn ^a   Peyer, Anne Kathrin ^a   Török, Michael ^a   Küsters, Ernst ^b   Drewe, Jürgen ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Confocal microscopy; Drug interactions; HMG CoA reductase inhibitors; In vitro; P glycoprotein; Rhodamine; Statins

Indexed keywords

ATORVASTATIN; ATORVASTATIN ACID; ATORVASTATIN LACTONE; ATORVASTATIN METHYL ESTER; FLUINDOSTATIN; GLYCOPROTEIN P; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOVASTATIN ACID; LOVASTATIN LACTONE; MEVINOLIN; PRAVASTATIN; RHODAMINE 123; SIMVASTATIN; SIMVASTATIN ACID; SIMVASTATIN LACTONE; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; ASSAY; CELL TRANSPORT; CONCENTRATION RESPONSE; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG SCREENING; ENZYME INHIBITION; FLUOROMETRY; GENE OVEREXPRESSION; LEUKEMIA CELL; MONOCYTE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 0035076611     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjp.0703920     Document Type: Article

References (50)

1. Biochemical, cellular, and pharmacological aspects of the multidrug transporter
2. The interaction of diltiazem with lovastatin and pravastatin
3. In vivo circumvention of P-glycoprotein-mediated multidrug resistance of tumor cells with SDZ PSC 833
4. 'Fire and forget?' - Pharmacological considerations in coronary care
5. Atorvastatin coadministration may increase digoxin concentrations by inhibition of intestinal P-glycoprotein-mediated secretion
6. Metabolic disposition of simvastatin in patients with T-tube drainage
7. Metabolism and drug interactions of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in transplant patients: Are the statins mechanistically similar?
8. New insights into the pharmacodynamic and pharmacokinetic properties of statins
9. Clinical implications of the biopharmaceutical properties of fluvastatin
10. HMG-CoA reductase mediates the biological effects of retinoic acid on human neuroblastoma cells: Lovastatin specifically targets P- glycoprotein-expressing cells
11. Mibefradil significantly increases serum concentrations of atorvastatin but not pravastatin
12. HIV protease inhibitor ritonavir: A more potent inhibitor of P-glycoprotein than the cyclosporine analog SDZ PSC 833
13. Structure-activity-relationship studies on modulators of the multidrug transporter P-glycoprorein - An overview
14. Mechanism of action of P-glycoprotein in relation to passive membrane permeation
15. Epithelial transport of anthelmintic ivermectin in a novel model of isolated proximal kidney tubules
16. Intestinal secretion of intravenous talinolol is inhibited by luminal R-verapamil
17. Biotransformation of lovastatin. V. Species differences in in vivo metabolite profiles of mouse, rat, dog, and human
18. Functional polymorphisms of the human multidrug-resistance gene: Multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo
19. A novel human hepatic organic anion transporting polypeptide (OATP2). Identification of a liver-specific human organic anion transporting polypeptide and identification of rat and human hydroxymethylglutaryl- CoA reductase inhibitor transporters
20. Intestinal secretion of drugs: The role of P-glycoprotein and related drug efflux systems in limiting oral drug absorption
21. The effect of drug lipophilicity on P-glycoprotein-mediated colchicine efflux at the blood-brain barrier
22. Inter-relationship between substrates and inhibitors of human CYP3A and P-glycoprotein
23. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences
24. Surface activity and concentration dependent intestinal permeability in the rat
25. Jejunal permeability and hepatic extraction of fluvastatin in humans
26. Role of intestinal P-glycoprotein (mdrl) in interpatient variation in the oral bioavailability of cyclosporine
27. Rhabdomyolysis associated with concomitant use of atorvastatin and cyclosporine
28. In vitro myotoxicity of the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, pravastatin, lovastatin, and simvastatin, using neonatal rat skeletal myocytes
29. Indirect coupling of organic anion secretion to sodium in teleost (Paralichthys lethostigma) renal tubules
30. The interaction of diltiazem with simvastatin
31. Metabolic interactions between mibefradil and HMG-CoA reductase inhibitors: Linking in vitro with in vivo information
32. Molecular aspects of hepatobiliary transport
33. SDZ PSC 833 and SDZ 280-446 are the most active of various resistance-modifying agents in restoring rhodamine-123 retention within multidrug resistant P388 cells
34. Metabolic interactions between mibefradil and HMG-CoA reductase inhibitors: An in vitro investigation with human liver preparations
35. The physiological function of drug-transporting P-glycoproteins
36. P-glycoprotein-mediated Hoechst 33342 transport out of the lipid bilayer
37. Availability of PSC833, a substrate and inhibitor of P-glycoproteins, in various concentrations of serum
38. Intestinal brush-border membrane transport of monocarboxylic acids mediated by proton-coupled transport and anion antiport mechanisms
39. Variable activation of lovastatin by hydrolytic enzymes in human plasma and liver
40. In vitro comparative inhibition profiles of major human drug metabolising cytochrome P450 isozymes (CYP2C9, CYP2D6 and CYP3A4) by HMG-CoA reductase inhibitors
41. Transport mechanism of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors at the blood-brain barrier
42. Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: Implications for drug delivery and activity in cancer chemotherapy
43. Mibefradil is a P-glycoprotein substrate and a potent inhibitor of both P-glycoprotein and CYP3A In vitro
44. In vitro flow cytometry method to quantitatively assess inhibitors of P-glycoprotein
45. Atorvastatin transport in the Caco-2 cell model: Contributions of P-glycoprotein and the proton-monocarboxylic acid co-transporter
46. Biliary excretion of pravastatin in rats: Contribution of the excretion pathway mediated by canalicular multispecific organic anion transporter
47. The contribution of P-glycoprotein to pharmacokinetic drug-drug interactions
48. Physical-chemical properties shared by compounds that modulate multidrug resistance in human leukemic cells
49. Development of an immobilized P-glycoprotein stationary phase for online liquid chromatographic determination of drug-binding affinities